News | March 06, 2024
Bayer strengthens pharma portfolio with new cardiology drug acoramidis
Acquisition of exclusive commercialization rights for European markets
Acquisition of exclusive commercialization rights for European markets
An accomplished R&D leader and champion of the application of AI to drug discovery
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
Juergen Eckhardt joined Bayer in 2016 to help start Leaps by Bayer
Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer’s fully integrated $20 billion healthcare business
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Subscribe To Our Newsletter & Stay Updated
